Finance

Lists
600085:SHA
Beijing Tong Ren Tang Co Ltd
CNÂ¥24,28
+1,46%
(+0,35) 1D
9 Okt., 15:00:00 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600085...
Open
CNÂ¥23,93
High
CNÂ¥24,45
Low
CNÂ¥23,89
Mkt. cap
33,30 mjd
Avg. vol.
4,63 m
Volume
9,94 m
Dividend
2,06%
Quarterly dividend
CNÂ¥0,12
Ex-dividend date
01 Jul. 2026
P/E ratio
34,33
52-wk high
CNÂ¥35,87
52-wk low
CNÂ¥21,87
EPS
CNÂ¥0,71
Shares outstanding
1,37 mjd
No. of employees
17 k
Open
CNÂ¥23,93
High
CNÂ¥24,45
Low
CNÂ¥23,89
Mkt. cap
33,30 mjd
Avg. vol.
4,63 m
Volume
9,94 m
Dividend
2,06%
Quarterly dividend
CNÂ¥0,12
Ex-dividend date
01 Jul. 2026
P/E ratio
34,33
52-wk high
CNÂ¥35,87
52-wk low
CNÂ¥21,87
EPS
CNÂ¥0,71
Shares outstanding
1,37 mjd
No. of employees
17 k
News stories
From web sources and news partners
Profile
Tong Ren Tang is a Chinese pharmaceutical company founded in 1669. It is now the largest producer of traditional Chinese medicine. The company headquarters are in Beijing, where they engage in both manufacturing and retail sales. It operates drug stores, predominantly in Chinese-speaking regions. Tong Ren Tang is considered one of the "Big 4" traditional Chinese medicine brands still in existence. The four companies include: Guangyuyuan, Guangzhou Chen Liji, Beijing Tong Ren Tang, and Hangzhou Hu Qing Yu Tang. Tong Ren Tang, and GuangYuYuan have been officially recognized as "China Time-Honored Brands" by the Ministry of Commerce of the People's Republic of China. Wikipedia
About Beijing Tong Ren Tang Co Ltd
CEO-
Employees17,3 k
Founded1669
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
3,54 mjd
3,95 mjd
4,66 mjd
3,72 mjd
Cost of goods sold
1,97 mjd
2,50 mjd
2,72 mjd
2,17 mjd
Cost of revenue
1,97 mjd
2,50 mjd
2,72 mjd
2,17 mjd
Research and development expenses
53,41 m
144,52 m
51,64 m
74,50 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,10 mjd
1,30 mjd
1,13 mjd
1,04 mjd
Operating expense
1,16 mjd
1,52 mjd
1,23 mjd
1,16 mjd
Total operating expenses
3,13 mjd
4,02 mjd
3,95 mjd
3,33 mjd
Operating income
408,67 m
-73,33 m
709,73 m
383,76 m
Other non operating income
-3,64 m
-4,50 m
-3,96 m
-4,53 m
EBT including unusual items
346,57 m
67,54 m
748,37 m
431,21 m
EBT excluding unusual items
418,62 m
-56,72 m
750,60 m
414,06 m
Income tax expense
88,79 m
27,32 m
131,64 m
112,60 m
Effective tax rate
25,62%
40,44%
17,59%
26,11%
Other operating expenses
-1,80 m
58,15 m
29,98 m
47,32 m
Net income
232,06 m
11,82 m
471,18 m
255,01 m
Net profit margin
6,56%
0,30%
10,10%
6,86%
Earnings per share
-
-
-
-
Interest and investment income
45,55 m
48,93 m
70,91 m
59,45 m
Interest expense
-30,03 m
-28,19 m
-26,08 m
-24,57 m
Net interest expenses
15,52 m
20,74 m
44,83 m
34,88 m
Depreciation and amortization charges
-
-
-
-
EBITDA
495,57 m
18,15 m
801,21 m
477,52 m
Gain or loss from assets sale
1,87 m
-25,11 m
-
-10,41 m
AI content may include mistakes. Learn more
Google-programme